CEO and CFO of Probi AB (publ) acquires shares

Tom Rönnlund, CEO of Probi AB (publ), has acquired 1,000 shares in Probi AB on May 2, 2019. After the transaction Tom Rönnlund holds a total of 1,000 shares. The same day Henrik Lundkvist, CFO of Probi AB (publ), has acquired 150 shares in Probi AB. After the transaction Henrik Lundkvist holds a total of 150 shares.

The transactions have been reported to the Swedish Financial Supervisory authority.

FOR FURTHER INFORMATION, CONTACT:
Henrik Lundkvist, CFO, Probi, tel +46 46 286 89 41, e-mail: henrik.lundkvist@probi.com

ABOUT PROBI
Probi AB is a Swedish publicly traded bioengineering company. Probi’s vision is to help people live healthier lives by delivering effective and well-documented probiotics, with proven health benefits based on scientific research. Founded by scientists in Sweden in 1991, Probi is a multinational company, active in more than 40 markets around the world and holding over 400 patents worldwide. In 2018, Probi had net sales of MSEK 604. The Probi share is listed on Nasdaq Stockholm, Mid Cap. Probi had about 4,000 shareholders on December 31, 2018. Read more at www.probi.com. 

Tags:

About Us

Probi® is a global company focused exclusively on researching, manufacturing, and delivering probiotics for supplements and functional food. We are experts at managing stable, live bacteria from R&D through every stage of the manufacturing process and are dedicated to making the health-enhancing benefits of probiotics available to people everywhere. Our health concepts, formulations, and formats are supported by robust clinical documentation. Since our founding in 1991 at Sweden’s Lund University, Probi has expanded its operations to more than 40 markets. We hold more than 400 patents globally. Read more at www.probi.com. Probi® is a registered trademark of Probi AB.

Contacts

Subscribe

Documents & Links